Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Vor Biopharma, Inc.

Vor Biopharma, Inc.

VOR

0.00

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ: VOR) with a Neutral and raises the price target from $18 to $27.